Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cream aims to stop vitiligo relapse after repigmentation

NCT ID NCT06446063

Disease control Sponsor: Pierre Fabre Dermo Cosmetique Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tested a cosmetic cream called RV5098A to see if it could help adults with vitiligo keep their facial pigmentation after successful repigmentation treatment. Vitiligo causes white patches on the skin, and even after treatment, about 40% of people lose color again within a year. The study enrolled 19 participants who applied the cream twice daily to their entire face. However, the trial was terminated early, so we have limited data on whether it works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
RV5098A (a cosmetic cream)
What this could lead to
If it works, this could help people with vitiligo keep their skin color longer after repigmentation treatment.
What could go wrong
The trial was terminated early with only 19 participants, so results are limited. It is a cosmetic product, not a drug, and may not provide lasting benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

19 people

The number who actually took part.

Started

May 2024

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects will be enrolled from the investigator's outpatient's reception and/or from the database of the centre. The subjects corresponding to eligibility criteria may receive a phone call, a letter or an e-mail proposing to participate to the clinical study.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Criteria related to the population: \- Subject aged between 18 and 75 years included. Criteria related to the disease: * Subject with facial vitiligo, regardless of its duration. * having a sufficient repigmentation rate of the vitiligo after repigmenting treatment Criteria related to treatments and/or products: \- Subject responder to a repigmenting treatment Non-inclusion Criteria: Criteria related to the diseases / skin condition: * Subject with active vitiligo. * Subject with spontaneous repigmentation without treatment. * Subject having other dermatological condition, an acute, chronic, or progressive disease or history of disease liable to interfere with the study assessments or considered by the Investigator hazardous for the subject or incompatible with the study requirements. Criteria related to treatments and/or products: * Systemic immunomodulatory treatment taken for another pathology, before inclusion, on-going or planned to be established during the study. * Any topical immunomodulatory treatment applied on the face for another pathology, on-going or planned to be established during the study. * Any other topical or systemic treatment established or modified during the previous weeks or planned to be established or modified during the study, liable to interfere with the evaluation of the efficacy according to the investigator's assessment. * Any dietary supplement for vitiligo within 4 weeks before the inclusion visit or planned to be established during the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Vitiligo are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Facies vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Vitiligo

Contacts and locations

Locations

  • COSDERMA

    Bordeaux, Gironde, 33000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.